search
Back to results

Treatment of Tracheostomy Granulomas

Primary Purpose

Granuloma, Tracheostomy

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Betadine
Silver Nitrate
Hydrocortisone Butyrate Cream, 1.0%
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Granuloma

Eligibility Criteria

31 Days - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children's Hospital Colorado inpatient or outpatient
  • 31 days to 17 years (inclusive)
  • Needs treatment for a tracheostomy granuloma

Exclusion Criteria:

  • Tracheostomy granuloma has been treated in the last two weeks

Sites / Locations

  • Children's Hospital Colorado

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Group 1: Betadine

Group 2: Silver Nitrate

Group 3: Hydrocortisone Butyrate Cream, 1.0%

Arm Description

Apply locally as needed.

Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.

Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.

Outcomes

Primary Outcome Measures

Success and Failure Rates for Each Treatment Method
Definition of success: The investigators are defining successful treatment of tracheostomy granulomas as a decrease in the frequency of granulomas over a six week observation period using the assigned treatment or partial or complete resolution of the granuloma. Partial resolution is defined as 25-75% resolution and complete resolution is defined as greater than 75% resolution. Definition of failure: The investigators are defining a treatment as a failure if during the six week observation period of using the assigned treatment, there is either no improvement in the resolution or there has been an increase in size or frequency of tracheostomy granulomas.
Categorical Improvement (Degree of Improvement)
Categorical success/failure data. the size of the granuloma will be measured and recorded. The percent circumference will also be measured. The approximate percent decrease in the granuloma size will be determined to determine the category subject's change in granuloma: i. Complete resolution: >90% improvement (Score = 4) ii. Improvement: 50 - 90% improvement (Score = 3) iii. Minimal improvement: < 50% improvement (Score = 2) iv. No improvement (Score = 1) v. Worsening (Score = 0)

Secondary Outcome Measures

Length of Time Between Administration of the Treatment and the Determination of Treatment Failure, if Applicable
Over the 6 week treatment period, the time from administration of the treatment to the time of treatment failure, if it occurs, will be evaluated and documented.

Full Information

First Posted
April 15, 2014
Last Updated
August 16, 2021
Sponsor
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT02116608
Brief Title
Treatment of Tracheostomy Granulomas
Official Title
Treatment of Tracheostomy Granulomas
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
September 2014 (Actual)
Primary Completion Date
September 5, 2019 (Actual)
Study Completion Date
September 5, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study plans to learn more about the different ways used to treat tracheostomy granulomas. Investigators want to see which standard of care method (steroid application, silver nitrate, or betadine) is more successful in treating tracheostomy granulomas.
Detailed Description
Upon joining the study patients will be assigned to one of the three treatment groups (steroid application, silver nitrate, and betadine). These three treatments are standard of care and patients would have been treated with one of them anyway. Patients will be followed for an observation period of six weeks with follow-up appointments, per standard of care, every two weeks (+/- 3 days) in order for a physician to evaluate if the treatment method is working. If during a follow-up visit, the physician determines the treatment method is not working, the follow-up period will end and participation in the study will be complete. In addition, if a patient is given a different form of treatment during the observation period, such as in the emergency department or through their primary care physician, the follow-up period will end and participation in the study will be complete.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Granuloma, Tracheostomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1: Betadine
Arm Type
Active Comparator
Arm Description
Apply locally as needed.
Arm Title
Group 2: Silver Nitrate
Arm Type
Active Comparator
Arm Description
Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
Arm Title
Group 3: Hydrocortisone Butyrate Cream, 1.0%
Arm Type
Active Comparator
Arm Description
Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
Intervention Type
Drug
Intervention Name(s)
Betadine
Intervention Description
Apply locally as needed.
Intervention Type
Drug
Intervention Name(s)
Silver Nitrate
Intervention Description
Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
Intervention Type
Drug
Intervention Name(s)
Hydrocortisone Butyrate Cream, 1.0%
Intervention Description
Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
Primary Outcome Measure Information:
Title
Success and Failure Rates for Each Treatment Method
Description
Definition of success: The investigators are defining successful treatment of tracheostomy granulomas as a decrease in the frequency of granulomas over a six week observation period using the assigned treatment or partial or complete resolution of the granuloma. Partial resolution is defined as 25-75% resolution and complete resolution is defined as greater than 75% resolution. Definition of failure: The investigators are defining a treatment as a failure if during the six week observation period of using the assigned treatment, there is either no improvement in the resolution or there has been an increase in size or frequency of tracheostomy granulomas.
Time Frame
Over 6 weeks
Title
Categorical Improvement (Degree of Improvement)
Description
Categorical success/failure data. the size of the granuloma will be measured and recorded. The percent circumference will also be measured. The approximate percent decrease in the granuloma size will be determined to determine the category subject's change in granuloma: i. Complete resolution: >90% improvement (Score = 4) ii. Improvement: 50 - 90% improvement (Score = 3) iii. Minimal improvement: < 50% improvement (Score = 2) iv. No improvement (Score = 1) v. Worsening (Score = 0)
Time Frame
Over 6 Weeks
Secondary Outcome Measure Information:
Title
Length of Time Between Administration of the Treatment and the Determination of Treatment Failure, if Applicable
Description
Over the 6 week treatment period, the time from administration of the treatment to the time of treatment failure, if it occurs, will be evaluated and documented.
Time Frame
Over 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
31 Days
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children's Hospital Colorado inpatient or outpatient 31 days to 17 years (inclusive) Needs treatment for a tracheostomy granuloma Exclusion Criteria: Tracheostomy granuloma has been treated in the last two weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeremy Prager, MD
Organizational Affiliation
1. University of Colorado School of Medicine, Department of Otolaryngology 2. Children's Hospital Colorado, Department of Pediatric Otolaryngology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
12514373
Citation
Yaremchuk K. Regular tracheostomy tube changes to prevent formation of granulation tissue. Laryngoscope. 2003 Jan;113(1):1-10. doi: 10.1097/00005537-200301000-00001.
Results Reference
background
PubMed Identifier
21996151
Citation
Chen C, Bent JP, Parikh SR. Powered debridement of suprastomal granulation tissue to facilitate pediatric tracheotomy decannulation. Int J Pediatr Otorhinolaryngol. 2011 Dec;75(12):1558-61. doi: 10.1016/j.ijporl.2011.09.007. Epub 2011 Oct 11.
Results Reference
background
PubMed Identifier
20425857
Citation
Al-Samri M, Mitchell I, Drummond DS, Bjornson C. Tracheostomy in children: a population-based experience over 17 years. Pediatr Pulmonol. 2010 May;45(5):487-93. doi: 10.1002/ppul.21206.
Results Reference
background
PubMed Identifier
22612258
Citation
McShane DB, Bellet JS. Treatment of hypergranulation tissue with high potency topical corticosteroids in children. Pediatr Dermatol. 2012 Sep-Oct;29(5):675-8. doi: 10.1111/j.1525-1470.2012.01724.x. Epub 2012 May 21.
Results Reference
background

Learn more about this trial

Treatment of Tracheostomy Granulomas

We'll reach out to this number within 24 hrs